北京商报讯(记者王寅浩实习记者宋雨盈)7月28日,恒瑞医药发布公告称,与英国企业GSK(葛兰素史克)达成协议,将HRS—9821项目的全球独家权利(不包括中国)和至多11个项目的全球独家许可的独家选择权(不包括中国)有偿许可给GSK。根据协议条款,GSK将向恒瑞医药支付总计5亿美元的首付款。 HRS—9821目前正处于临床开发阶段,可用于治疗慢性阻塞性肺病 (COPD),作为辅助维持治疗,无需...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.